Shaaltiel Yoseph 4
4 · Protalix BioTherapeutics, Inc. · Filed May 4, 2012
Insider Transaction Report
Form 4
Shaaltiel Yoseph
DirectorExecutive VP, R&D
Transactions
- Sale
Common Stock
2012-05-02$7.13/sh−300,000$2,139,000→ 463,754 total
Footnotes (1)
- [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.